Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 568 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord November 10, 2022 6-Yr-Old With Cerebral Palsy Receives Dream Gift After Learning To Walk. January 9, 2020 The Taylor Family Foundation gives £2.1m to support head and neck... December 12, 2022 Prostate cancer: Lessons Learned from My Breast Cancer June 23, 2021 Load more HOT NEWS Qué debo saber sobre los programas de emparejamiento de ensayos clínicos... For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily What Should People With Cancer Know About Alkaline Water? Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients...
